Mitochondrial Dysfunction in the Pathogenesis of Rett Syndrome: Implications for Mitochondria-Targeted Therapies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by mutations of the X-linked MECP2 gene. RTT affects predominantly females, and has a prevalence of roughly 1 in every 10,000 female births. Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease. In fact, several reports documented altered mitochondrial structure, and deficiencies in mitochondrial enzyme activity in different cells or tissues derived from RTT patients. With the identification of MECP2 as the causal gene, interest largely shifted towards defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology. Recently, though, interest in studying mitochondrial function in RTT has been reignited, at least in part due to observations suggesting systemic oxidative stress does play a contributing role in RTT pathogenesis. Here we review data relating to mitochondrial alterations at the structural and functional levels in RTT patients and model systems, and present a hypothesis for how the absence of MeCP2 could lead to altered mitochondrial function and elevated levels of cellular oxidative stress. Finally, we discuss the prospects for treating RTT using interventions that target specific aspects of mitochondrial dysfunction and/or oxidative stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990
Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism
MITCHELL, P. (1961) · Nature · doi:10.1038/191144a0 · Cited by 4,704
MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., & Zoghbi, H. Y. (2008) · Science · doi:10.1126/science.1153252 · Cited by 1,823
A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome
Guy, J., Hendrich, B., Holmes, M., Martin, J. E., & Bird, A. (2001) · Nature Genetics · doi:10.1038/85899 · Cited by 1,558
Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice
Chen, R. Z., Akbarian, S., Tudor, M., & Jaenisch, R. (2001) · Nature Genetics · doi:10.1038/85906 · Cited by 1,275 · cited 2×
“…(Johnston et al., 2001; Neul and Zoghbi, 2004), it is not surprising that the brain expresses the highest levels of MeCP2 in the body (Shahbazian et al., 2002), and the selective removal of MeCP2 from neurons is sufficient to induce a RTTlike phenotype in mice (Chen et al., 2001; Guy et al., 2001).”
BackgroundMitochondrial proton and electron leaks
Jastroch, M., Divakaruni, A. S., Mookerjee, S., Treberg, J. R., & Brand, M. D. (2010) · Essays in Biochemistry · doi:10.1042/bse0470053 · Cited by 829 · cited 12×
“In the absence of MeCP2, ANT1 would become de-repressed, leading to an elevation in its expression.”
BackgroundInfluentialNeuronal MeCP2 Is Expressed at Near Histone-Octamer Levels and Globally Alters the Chromatin State
Skene, P. J., Illingworth, R. S., Webb, S., Kerr, A. R. W., James, K. D., Turner, D. J., Andrews, R., & Bird, A. P. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.030 · Cited by 688 · cited 2×
“, 2008) by regulating both local and higher-order chromatin organization (Jones et al., 1998; Georgel et al., 2003; Skene et al., 2010).”
BackgroundDani, V. S., Chang, Q., Maffei, A., Turrigiano, G. G., Jaenisch, R., & Nelson, S. B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506071102 · Cited by 639 · cited 3×
“…Dysfunction in the Pathogenesis of Rett Syndrome: Implications for Mitochondria-Targeted Therapies Natalya Shulyakova 1, 2, Ana C. Andreazza 3, Linda R. Mills 2 and James H. Eubanks 1, 2, 4, 5* 1Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto,…”
BackgroundInfluentialA role for glia in the progression of Rett’s syndrome
Lioy, D. T., Garg, S. K., Monaghan, C. E., Raber, J., Foust, K. D., Kaspar, B. K., Hirrlinger, P. G., Kirchhoff, F., Bissonnette, J. M., Ballas, N., et al. (2011) · Nature · doi:10.1038/nature10214 · Cited by 496 · cited 2×
“, 2013), and the reactivation of Mecp2 in only astrocytes of MeCP2-null mice improves aspects of their RTT-like behavior (Lioy et al., 2011).”
BackgroundThe basal proton conductance of mitochondria depends on adenine nucleotide translocase content
Brand, M. D., Pakay, J. L., Ocloo, A., Kokoszka, J., Wallace, D. C., Brookes, P. S., & Cornwall, E. J. (2005) · Biochemical Journal · doi:10.1042/bj20050890 · Cited by 410
Chromatin Compaction by Human MeCP2
Georgel, P. T., Horowitz-Scherer, R. A., Adkins, N., Woodcock, C. L., Wade, P. A., & Hansen, J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305308200 · Cited by 305
Belichenko, P. V., Wright, E. E., Belichenko, N. P., Masliah, E., Li, H. H., Mobley, W. C., & Francke, U. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.22009 · Cited by 272
Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome
Kriaucionis, S., Paterson, A., Curtis, J., Guy, J., MacLeod, N., & Bird, A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01665-05 · Cited by 219
Kron, M., Howell, C. J., Adams, I. T., Ransbottom, M., Christian, D., Ogier, M., & Katz, D. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2159-12.2012 · Cited by 154 · cited 1×
“Through these mechanisms, MeCP2 functions as a key transcriptional control orchestrator that maintains homeostasis in different cells and systems throughout the body in accordance with local demands (Dani et al., 2005; Kron et al., 2012; Li et al., 2013).”
BackgroundSystemic oxidative stress in classic Rett syndrome
De Felice, C., Ciccoli, L., Leoncini, S., Signorini, C., Rossi, M., Vannuccini, L., Guazzi, G., Latini, G., Comporti, M., Valacchi, G., et al. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.016 · Cited by 148 · cited 2×
“…in blood and cerebrospinal fluid (Matsuishi et al., 1992; Lappalainen and Riikonen, 1994; Haas et al., 1995), altered electron transport chain (ETC) complex function (Kriaucionis et al., 2006; Gold et al., 2014), and evidence for increased oxidative damage (De Felice et al., 2009, 2011a,b, 2012).”
BackgroundOxidative brain damage in Mecp2-mutant murine models of Rett syndrome
De Felice, C., Della Ragione, F., Signorini, C., Leoncini, S., Pecorelli, A., Ciccoli, L., Scalabrì, F., Marracino, F., Madonna, M., Belmonte, G., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.006 · Cited by 126
Jin, L.-W., Horiuchi, M., Wulff, H., Liu, X.-B., Cortopassi, G. A., Erickson, J. D., & Maezawa, I. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2778-14.2015 · Cited by 88 · cited 3×
“, 2015), and in isolated Mecp2−/y microglia (Jin et al., 2015) provides further evidence that the absence of MeCP2 leads to impaired mitochondrial function.”
BackgroundOxidative stress in Rett syndrome
Sierra, C., Vilaseca, M. A., Brandi, N., Artuch, R., Mira, A., Nieto, M., & Pineda, M. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00369-2 · Cited by 79 · cited 2×
“In Sierra et al. (2001) showed a decrease in the activity of superoxide dismutase in erythrocytes from RTT patients, and an increase in plasma malondialdehyde, a marker of lipid peroxidation.”
BackgroundGold, W. A., Williamson, S. L., Kaur, S., Hargreaves, I. P., Land, J. M., Pelka, G. J., Tam, P. P. L., & Christodoulou, J. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.02.012 · Cited by 73
Oxidative stress in Rett syndrome: natural history, genotype, and variants
Leoncini, S., De Felice, C., Signorini, C., Pecorelli, A., Durand, T., Valacchi, G., Ciccoli, L., & Hayek, J. (2011) · Redox Report · doi:10.1179/1351000211y.0000000004 · Cited by 69
Park, M. J., Aja, S., Li, Q., Degano, A. L., Penati, J., Zhuo, J., Roe, C. R., & Ronnett, G. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109527 · Cited by 62 · cited 2×
“STRESS IN RETT SYNDROME TISSUES”
BackgroundRett syndrome: a mitochondrial disease?
Eeg-Olofsson, O., Al-Zuhair, A. G. H., Teebi, A. S., Daoud, A. S., Zaki, M., Besisso, M. S., & Al-Essa, M. M. N. (1990) · Journal of Child Neurology · doi:10.1177/088307389000500311 · Cited by 62 · cited 1×
“…elongated mitochondria with vacuolization and concentric membranous profiles, and oversized mitochondria that had fewer and shorter cristae than normal (Eeg-Olofsson et al., 1988, 1990; Ruch et al., 1989; Wakai et al., 1990; Dotti et al., 1993; Cornford et al., 1994; Cardaioli et al., 1999).”
BackgroundRedox imbalance and morphological changes in skin fibroblasts in typical Rett syndrome
Signorini, C., Leoncini, S., De Felice, C., Pecorelli, A., Meloni, I., Ariani, F., Mari, F., Amabile, S., Paccagnini, E., Gentile, M., et al. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/195935 · Cited by 61 · cited 1×
“More recently Signorini et al. (2014) reported significant increases in F4-Neuroprostanes (F4-NeuroPs), F2-IsoPs, NPBI, and 4-HNE PAs, together with a significant decrease in reduced glutathione (GSH)—one of the major non-enzymatic endogenous antioxidants—in skin fibroblasts from RTT patients.”
BackgroundAbnormal mitochondria in the Rett syndrome
Eeg-Olofsson, O., Al-Zuhair, A. G., Teebi, A. S., & Al-Essa, M. M. (1988) · Brain and Development · doi:10.1016/s0387-7604(88)80010-x · Cited by 58
Aberrant redox homoeostasis and mitochondrial dysfunction in Rett syndrome
Müller, M., & Can, K. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140071 · Cited by 50 · cited 2×
“…in RTT patients have provided tangible benefits supports the hypothesis that mitochondrial impairments linked to oxidative stress directly contribute to RTT pathogenesis, and are not simply secondary consequences that appear after full symptomatic progression has occurred (Müller and Can, 2014).”
BackgroundJanc, O. A., Hüser, M. A., Dietrich, K., Kempkes, B., Menzfeld, C., Hülsmann, S., & Müller, M. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00266 · Cited by 35 · cited 2×
“STRESS IN RETT SYNDROME TISSUES”
BackgroundOxidative metabolism in Rett syndrome. 2. Biochemical and molecular studies
Haas, R., Nasirian, F., Hua, X., Nakano, K., & Hennessy, M. (1995) · Neuropediatrics · doi:10.1055/s-2007-979735 · Cited by 22
Cited by
Rett syndrome: a neurological disorder with metabolic components
Kyle, S. M., Vashi, N., & Justice, M. J. (2018) · Open Biology · doi:10.1098/rsob.170216 · Cited by 213
Sun, J., Osenberg, S., Irwin, A., Ma, L.-H., Lee, N., Xiang, Y., Li, F., Wan, Y.-W., Park, I.-H., Maletic-Savatic, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111942 · Cited by 37
Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome
Zandl-Lang, M., Züllig, T., Trötzmüller, M., Naegelin, Y., Abela, L., Wilken, B., Scholl-Buergi, S., Karall, D., Kappos, L., Köfeler, H., et al. (2022) · Metabolites · doi:10.3390/metabo12040291 · Cited by 30
“RTT is also characterized by metabolic perturbations, such as elevated oxidative stress [10], mitochondrial dysfunction [11], but also dyslipidemia [12].”
BackgroundNeural precursor cells rescue symptoms of Rett syndrome by activation of the Interferon γ pathway
Frasca, A., Miramondi, F., Butti, E., Indrigo, M., Balbontin Arenas, M., Postogna, F. M., Piffer, A., Bedogni, F., Pizzamiglio, L., Cambria, C., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00144-9 · Cited by 9
“Such a wide spectrum of symptoms challenges the identi fi cation of effective pharmacological therapies for RTT.”
Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome
Audouard, E., Khefif, N., Gillet-Legrand, B., Nobilleau, F., Bouazizi, O., Stanga, S., Despres, G., Alves, S., Lamazière, A., Cartier, N., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060756 · Cited by 7
“Abnormalities in mitochondrial structure and function have been described in both RTT patients and Mecp2 -deficient mouse models [38,47–49].”
Background
Metadata
- Authors
- Shulyakova, N., Andreazza, A. C., Mills, L. R., & Eubanks, J. H.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-03-14
- Volume
- 11
- Pages
- 58-58
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2596220192
- Cited by
- 115
- References
- 27
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.